Coherus Oncology annual revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Coherus Oncology Revenue Growth & History (CHRS)
Coherus Oncology reported $42.2M in revenue for fiscal 2025, an increase of 59.81% from the previous fiscal year.
View full Coherus Oncology company overviewCoherus Oncology annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.2M | $15.8M | +59.81% |
| 2024 | 2024-12-31 | $26.4M | −$230.9M | −89.74% |
| 2023 | 2023-12-31 | $257.2M | $46.2M | +21.89% |
| 2022 | 2022-12-31 | $211.0M | −$115.5M | −35.37% |
| 2021 | 2021-12-31 | $326.6M | −$149.3M | −31.37% |
| 2020 | 2020-12-31 | $475.8M | $119.8M | +33.63% |
| 2019 | 2019-12-31 | $356.1M | $356.1M | — |
| 2018 | 2018-12-31 | $0 | −$1.6M | −100.00% |
| 2017 | 2017-12-31 | $1.6M | −$187.9M | −99.18% |
| 2016 | 2016-12-31 | $189.5M | $159.4M | +530.72% |
| 2015 | 2015-12-31 | $30.0M | −$1.1M | −3.42% |
| 2014 | 2014-12-31 | $31.1M | $28.4M | +1030.72% |
| 2013 | 2013-12-31 | $2.8M | $852,000 | +44.87% |
| 2012 | 2012-12-31 | $1.9M | — | — |
Coherus Oncology quarterly revenue
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.3M | $4.1M | +39.53% |
| Q1 2026 | 2026-03-31 | $12.3M | $4.7M | +61.99% |
| Q4 2025 | 2025-12-31 | $12.7M | $5.0M | +64.85% |
| Q3 2025 | 2025-09-30 | $11.6M | $5.5M | +91.19% |
| Q2 2025 | 2025-06-30 | $10.3M | −$42,000 | −0.41% |
| Q1 2025 | 2025-03-31 | $7.6M | $5.3M | +229.25% |
| Q4 2024 | 2024-12-31 | $7.7M | −$83.8M | −91.55% |
| Q3 2024 | 2024-09-30 | $6.1M | −$68.5M | −91.88% |
| Q2 2024 | 2024-06-30 | $10.3M | −$48.4M | −82.46% |
| Q1 2024 | 2024-03-31 | $2.3M | −$30.1M | −92.88% |
| Q4 2023 | 2023-12-31 | $91.5M | $46.2M | +101.81% |
| Q3 2023 | 2023-09-30 | $74.6M | $29.1M | +64.16% |
| Q2 2023 | 2023-06-30 | $58.7M | −$1.4M | −2.39% |
| Q1 2023 | 2023-03-31 | $32.4M | −$27.7M | −46.04% |
| Q4 2022 | 2022-12-31 | $45.4M | −$28.0M | −38.19% |
| Q3 2022 | 2022-09-30 | $45.4M | −$37.1M | −44.94% |
| Q2 2022 | 2022-06-30 | $60.2M | −$27.5M | −31.37% |
| Q1 2022 | 2022-03-31 | $60.1M | −$22.9M | −27.60% |
| Q4 2021 | 2021-12-31 | $73.4M | −$37.0M | −33.55% |
| Q3 2021 | 2021-09-30 | $82.5M | −$31.0M | −27.34% |
| Q2 2021 | 2021-06-30 | $87.6M | −$48.0M | −35.40% |
| Q1 2021 | 2021-03-31 | $83.0M | −$33.1M | −28.53% |
| Q4 2020 | 2020-12-31 | $110.4M | −$13.4M | −10.85% |
| Q3 2020 | 2020-09-30 | $113.6M | $1.9M | +1.67% |
| Q2 2020 | 2020-06-30 | $135.7M | $52.2M | +62.61% |
| Q1 2020 | 2020-03-31 | $116.2M | $79.1M | +213.17% |
| Q4 2019 | 2019-12-31 | $123.9M | $123.9M | — |
| Q3 2019 | 2019-09-30 | $111.7M | $111.7M | — |
| Q2 2019 | 2019-06-30 | $83.4M | $83.4M | — |
| Q1 2019 | 2019-03-31 | $37.1M | $37.1M | — |
| Q4 2018 | 2018-12-31 | $0 | $0 | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | −$1.4M | −100.00% |
| Q1 2018 | 2018-03-31 | $0 | −$161,000 | −100.00% |
| Q4 2017 | 2017-12-31 | $0 | −$844,000 | −100.00% |
| Q3 2017 | 2017-09-30 | $0 | −$162.8M | −100.00% |
| Q2 2017 | 2017-06-30 | $1.4M | −$12.7M | −90.08% |
| Q1 2017 | 2017-03-31 | $161,000 | −$12.2M | −98.70% |
| Q4 2016 | 2016-12-31 | $844,000 | −$9.4M | −91.72% |
| Q3 2016 | 2016-09-30 | $162.8M | $155.7M | +2172.01% |
| Q2 2016 | 2016-06-30 | $14.1M | $7.2M | +104.89% |
| Q1 2016 | 2016-03-31 | $12.4M | $6.5M | +112.72% |
| Q4 2015 | 2015-12-31 | $10.2M | $3.7M | +57.06% |
| Q3 2015 | 2015-09-30 | $7.2M | −$8.9M | −55.35% |
| Q2 2015 | 2015-06-30 | $6.9M | $1.9M | +38.29% |
| Q1 2015 | 2015-03-31 | $5.8M | $2.2M | +61.57% |
| Q4 2014 | 2014-12-31 | $6.5M | $5.3M | +427.03% |
| Q3 2014 | 2014-09-30 | $16.1M | $15.5M | +3072.33% |
| Q2 2014 | 2014-06-30 | $5.0M | $4.5M | +879.29% |
| Q1 2014 | 2014-03-31 | $3.6M | $3.1M | +610.67% |
| Q4 2013 | 2013-12-31 | $1.2M | — | — |
| Q3 2013 | 2013-09-30 | $506,000 | — | — |
| Q2 2013 | 2013-06-30 | $507,000 | — | — |
| Q1 2013 | 2013-03-31 | $506,000 | — | — |
Coherus Oncology revenue growth trends
Over the last five reported fiscal years, revenue declined from $475.8M to $42.2M, a compound annual decline of 38.41%. Coherus Oncology's latest reported quarter, Q2 2026, generated $14.3M in revenue, an increase of 39.53% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Coherus Oncology source filings ↗